Exelixis
EXEL
#1695
Rank
HK$77.41 B
Marketcap
HK$271.08
Share price
0.52%
Change (1 day)
66.21%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of September 2024 : HK$23.04 Billion

According to Exelixis's latest financial reports the company's total assets are HK$23.04 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year Total assets Change
2023-12-31HK$22.97 B-4.24%
2022-12-31HK$23.99 B17.64%
2021-12-31HK$20.40 B23.12%
2020-12-31HK$16.56 B12.82%
2019-12-31HK$14.68 B31.86%
2018-12-31HK$11.13 B117.54%
2017-12-31HK$5.11 B10.83%
2016-12-31HK$4.61 B79.34%
2015-12-31HK$2.57 B2.73%
2014-12-31HK$2.50 B-35.75%
2013-12-31HK$3.90 B-30.18%
2012-12-31HK$5.58 B82.99%
2011-12-31HK$3.05 B8.79%
2010-12-31HK$2.80 B5.45%
2009-12-31HK$2.66 B-14.2%
2008-12-31HK$3.10 B-3.42%
2007-12-31HK$3.21 B4.49%
2006-12-31HK$3.07 B19.22%
2005-12-31HK$2.57 B13.94%
2004-12-31HK$2.26 B-18.36%
2003-12-31HK$2.77 B4.87%
2002-12-31HK$2.64 B-2.15%
2001-12-31HK$2.70 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
HK$604.65 B 2,524.37%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$1.082 T 4,598.71%๐Ÿ‡ซ๐Ÿ‡ท France
HK$914.75 B 3,870.30%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$729.03 B 3,064.23%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$707.34 B 2,970.08%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$1.387 T 5,922.64%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$1.708 T 7,314.03%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.39 B-98.30%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.78 B-96.58%๐Ÿ‡บ๐Ÿ‡ธ USA